Drug Trial Radar · NCT06125041
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
Last checked: Nov 20, 2026Latest source record: Nov 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Oct 30, 2023
Primary completion
Jul 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Qianfoshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.
Conditions
- Extensive Small Cell Lung Cancer
Interventions
Adebelizumab+Carboplatin+Etoposide+Concurrent RadiotherapyDrug
Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survivalTime frame: 18 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.